The immunohistochemistry market is projected to reach USD 2,671.9 million by 2025 from USD 1,942.3 million in 2020, at a CAGR of 6.6% during the forecast period.
Increasing incidence of chronic diseases and technological advancements in IHC are set to drive the IHC market.
The increasing incidence and prevalence of cancer, technological advancements in IHC, and the availability of reimbursement for IHC tests are the major factors driving the growth of this market. However, the high degree of consolidation is expected to restrain the growth of this market during the forecast period
By antibodies type, the primary antibodies accounted for the fasted growing antibody segment of the IHC market
The antibodies segment includes primary antibodies and secondary antibodies. The primary antibodies segment accounted for the fastest-growing IHC antibody market.
Factors such as improved approval rate for therapeutic antibodies by regulatory authorities, increasing adoption of targeted immunotherapy and increased R&D expenditure of pharmaceutical and biotechnology companies.
Also, the mandatory use of primary antibodies in IHC protocols and their extensive application in diverse diagnostic and research areas have resulted in continuous demand for these antibodies.
By equipment type, the slide-staining systems segment accounted for the largest share of the IHC equipment market
Based on equipment type, the IHC equipment segment is further divided into slide-staining systems, tissue processing systems, slide scanners, and other equipment (automated cover slippers, microtomes, paraffin dispensers, tissue microarrays, and slide labelers).
The slide-staining systems accounted for the largest share of the IHC market, by the equipment. Development of high-throughput staining systems is one of the major factor driving market growth.
Asia Pacific: The fastest-growing region in the IHC market.
The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to the large population in emerging economies such as China, India, and Japan; rising prevalence of chronic diseases; rising demand for quality medical care; and the increasing healthcare spending are expected to boost the IHC market in the Asia Pacific.
North America: the largest share of the IHC market
North America accounted for the largest share of the IHC market.
The large share of this segment can primarily be attributed to the presence of major players operating in the IHC market in the US, rising incidence of cancer and infectious diseases, and the increasing adoption of companion diagnostic assay kits.
For more information, visit www.researchandmarkets.com